| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3376503 | Journal of Infection | 2007 | 4 Pages |
Abstract
When choosing between currently acceptable brucellosis regimens, medical personnel prefer convenience, even at the cost of a slightly higher relapse percentage. Future trials should evaluate shorter triple regimens. Enhancement of awareness on the disease and its principles may increase therapeutic cost effectiveness.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
G. Pappas, V. Siozopoulou, N. Akritidis, M.E. Falagas,